Life
Science

Physics & Engineering

Sortieren nach: Datum | Licensing Manager

Es wurden 31 Technologieangebote gefunden

Bisphosphonates as Potential Drug Candidates for Inflammatory Lung Diseases

15.02.2012 | Ref.Nr. 09061

Life Science › Pharma&Biotech

Biphosphonate with a prolonged carbon chain.Recent findings in animal models underline the potential role of the acid sphingomyelinase (aSMase) as an important drug target in inflammatory lung diseases like acute lung injury (ALI) - the main cause of death in intensive care units -, acute respiratory distress syndrome (ARDS), lung emphysema, and cystic fibrosis.

The invention offers simple geminal bisphosphonates with a prolonged carbon chain as potent and selective inhibitors of the acid sphingomyelinase. The compounds can be synthesized in a one-step or two-step procedure and show clear inhibition of cell death in vitro. First ex vivo data in rats show a reduction of platelet activating factor (PAF) – induced pulmonary edema in the presence of the bisphosphonates by at least 50 percent. Aerosols of bisphosphonates may be possible applicants for the treatment of pulmonary diseases.

Besides their use in inflammatory lung diseases the bisphosphonates with prolonged carbon chain may be used as a treatment option for cystic fibrosis and atherosclerosis.

IP Rights
EP Application (08/2009).
PCT Application (08/2010).
A PCT application was filed in August 2010.

Patent Owner
Humboldt-Universität zu Berlin
Rheinisch-Westfälische
Technische Hochschule Aachen (RWTH)

Application Area:

Drug candidates for the treatment of inflammatory lung diseases, cystic fibrosis and atherosclerosis.

Development Stage: Ex vivo

Schlagworte: Acid Sphingomyelinase, athero-sclerosis, bisphosphonate, cystic fibrosis, inflammatory lung diseases, Inhibitor,

Weitere Kategorien: Life Science, Medical Devices, Pharma & Biotech

Licensing Manager: Dr. Bettina Büttner

T +49 30 2125 4835

F +49 30 2125 4822

bettina.buettner@ipal.de

Suitable Industry: Pharmaceuticals

Benefits:

Neutral sphingomyelinase is not influenced
First ex-vivo data in a PAF-induced edema rat model showed clear edema reduction by 50percent
Inhibition of dexamethasone induced apoptosis was proven in vitro
Substances can easily be synthesized in a one-step or two-step procedure
Prolongation from 6 to 8 C-atoms shows 40times higher inhibition rate

C3bot Peptides as Drugs for the Treatment of Traumatic or Degenerative Neuronal Injury

21.12.2011 | Ref.Nr. 08167

Download as PDF PDF Download Share

Life Science › Pharma&Biotech

Figure : Neurocyte Picture: Höltje et al. 2009Background
Peptide fragments of the C3 exoenzyme of Clostridium botulinum have been found to have neuritogenic effects on neurons as well as regenerative proper-ties in an animal model (mouse). The peptides represent promising drug candidates for the treatment of neurodegenerative disorders such as Morbus Alzheimer, Parkinson, Huntington chorea but also for spinal cord injury and traumatic brain injury.enic effects on neurons as well as regenerative properties in an animal model (mouse).

Technology
We offer neuron-specific short peptides for the treatment of neurodegene-rative disorders. Whereas a 26mer peptide stimulates both, dendritic and axonal growth, a 15mer peptide selectively promotes axonal growth. Both, the 15mer and the 26mer peptide trigger a strong transient activation of RhoA which mimics the physiological conditions of RhoA activation / inactivation cycles.
These properties make the peptides suitable for repeated administration and long term treatments. As the peptides only act on neurons and not on microglia or astrocytes, there is no risk for neuronal inflammation or glia scar formation.

IP Rights
PCT application in 2010
National applications in USA/Europe in 2011

Patent Owner
Charité – Universitätsmedizin Berlin
Hannover Medical School

Application Area:

Drug candidates for the treatment of neurodegenerative disorders

Development Stage: In vitro / in vivo

Schlagworte: drug candi-date, Huntington cho-rea, Morbus Alzheimer, neurodegenerative disorders, Neuron-specific peptides, spinal cord injury, traumatic brain injury,

Weitere Kategorien: Life Science, Pharma & Biotech

Licensing Manager: Dr. Janin Hofmann

T +49 30 2125 4828

F +49 30 2125 4822

janin.hofmann@ipal.de

Benefits:

Physiological acting neuritogenic drug – small size and effective in nanomolar concentrations
Act neuron-specific -> reduced risk for neuronal inflammation or glia scar formation
Short peptides with low antigenicity and good kinetics
Broad application areas: Spinal cord injury, traumatic brain injury, Morbus Alzheimer, Parkinson, Huntington Chorea, etc.
In vivo data on spinal cord injury model show regenerative properties

Novel Screening Method for Agents suitable for Therapy of Alzheimer´s Disease

28.10.2011 | Ref.Nr. 07081

Download as PDF PDF Download Share

Life Science › Pharma&Biotech

Technology
We offer a screening method that allows the detection of novel drug candidates for the prophylaxis and causative therapy of Alzheimer’s Disease.

The identified drugs influence the substrat-enzyme interaction between amyloid precursor protein (APP) and gamma-secretase in a way that less Amyloid-β-peptide (Aβ42) is produced. Furthermore they have the ability to bind selectively and with high affinity the APP-GxxxG-motif and can pass the blood-brain barrier. It was shown that a drug capable of binding the APP GxxxG motif is weakening or inhibiting the dimerization of the APP trans-membrane sequence, leading to a decreased generation of Aβ42.

IP Rights
EP patent application was filed in November 2007.
PCT patent application was filed in November 2008.
US application was filed in April 2010.

Origin
Freie Universiät Berlin

Application Area:

Drug screening

Development Stage: Product

Schlagworte: Alzheimer Disease, Drug screening,

Weitere Kategorien: Diagnostics, Life Science, Research Tools, Pharma & Biotech

Licensing Manager: Rafaela Kunz

T +49 30 2125 4825

F +49 30 2125 4822

rafaela.kunz@ipal.de

Suitable Industry: Pharmaceuticals, Research & Development

Benefits:

Reliable, rapid, and easy screening assay for the identification of novel drug candidates
Applicable to blood samples

Assay for the Diagnosis of Alzheimer’s Disease based on the Determination of the Ratio of Aß38:Aß42

28.10.2011 | Ref.Nr. 06021

Download as PDF PDF Download Share

Life Science › Pharma&Biotech

Backgorund
Processing of the amyloid precursor protein (APP) by ß-and γ -secretases leads to the generation of amyloid-ß (Aß) peptides, which are the toxic agents in the pathogenesis of Alzheimer`s Disease. γ –secretase cleaves at variable sites producing Aß peptides with different C-termini, of which particularly Aß42 contributes to cytotoxicity and amyloid accumulation in Alzheimer Disease.

We discovered that dimerization of the APP trans-membrane sequence is mediated by glycine residues G29 and G33 of the three consecutive GxxxG motifs promoting helix-helix interactions. Mutations at the glycine positions attenuate the TMS dimerization strength and specifically reduce generation of Aß42. The level of reduced Aß42 is counterbalanced by increased Aß38, whereas the level of Aß40 remains unaffected.

Technology
We offer a novel assay for the diagnosis of early and late stages of Alzheimer’s Disease. The assay is very easy to use and allows a rapid and reliable detection of Aß38:Aß42. The ratio is used to make the diagnosis.

IP Rights
European Patent application was filed in June 2006.
PCT application was filed in April 2007.
Patent applications were filed in US, JP, IN, CN, CA, FR, GB, IT, ES, DE.

Origin
Freie Universität Berlin

Application Area:

Diagnosis of Alzheimer disease at all stages

Development Stage: Product

Schlagworte: Alzheimer diagnosis, Assay, Aß38, Aß42, Better early diagnosis,

Weitere Kategorien: Diagnostics, Life Science, Research Tools, Pharma & Biotech

Licensing Manager: Rafaela Kunz

T +49 30 2125 4825

F +49 30 2125 4822

rafaela.kunz@ipal.de

Suitable Industry: Diagnostics, Pharmaceuticals

Benefits:

Suitable for diagnosing Alzheimer at early stage of disease
Reliable, easy, and rapid diagnosis
Screening of blood samples

Pharmaceutical Composition for the Treatment of Solar Urticaria

25.08.2011 | Ref.Nr. 09093

Download as PDF PDF Download Share

Life Science › Pharma&Biotech

Background
Solar urticaria is an uncommon but well-recognized disorder characterized by the early onset of itching, erythema, and whealing after exposure to UVA, visible light, less commonly UVB and rarely infrared radiation. Typically, symptoms occur within minutes after solar radiation and are limited to sun-exposed skin areas.

Technology
We offer a lidocaine/prilocaine combination for the treatment or prevention of solar urticaria. Up to now the lidocaine/prilocaine combination is used for dermal anesthesia (marketed as EMLA). The inventors demonstrated in two of two patients with solar urticaria and an action spectrum to UVA that the combination of lidocaine and prilocaine protects the tissue and inhibits triggering of the cascade which usually leads to typical symptoms of solar urticaria.
The topical application of a lidocaine/prilocaine mixture prior to UV-provocation stabilizes or inhibits sensory nerve fibres of the skin and induces down-regulation or inhibition of the release of pro-inflammatory neuropeptides. Due to this more general concept it is assumed that (1) other local anesthetics in addition to lidocaine and prilocaine, (2) lidocaine alone or prilocaine alone, and (3) lidocaine and/or prilocaine in combination with other local anesthetics are effective as well.

IP Rights

A European patent application was filed in April 2010.

Patent Owner
Charité – Universitätsmedizin Berlin

Application Area:

Treatment or prevention of solar urticaria

Development Stage: Clinical

Schlagworte: Anesthetics, Lidocaine, Prilocaine, Skin, Solar urticaria,

Weitere Kategorien: Life Science, Pharma & Biotech

Licensing Manager: Dr. Janin Hofmann

T +49 30 2125 4828

F +49 30 2125 4822

janin.hofmann@ipal.de

Suitable Industry: Pharmaceutical industry

Benefits:

Topical application on skin parts of patients leads to a reliable reduction of clinical symptoms of solar urticaria
The treatment is very effective and is associated with low side-effects
Topical application directly on the sun-exposed skin is more convenient to the patient than other application routes
The individual active ingredients of the pharmaceutical composition are already clinical approved for anesthesia
Low cost treatment

One-Plasmid Systems for Blue-light-regulated Gene Expression in Prokaryotes

18.08.2011 | Ref.Nr. 11043

Download as PDF PDF Download Share

Life Science › Pharma&Biotech

Background
Protein expression systems are very widely used in the life sciences, biotechnology and medicine. Traditional strategies for recombinant protein expression involve the transformation of a gene expression vector into prokaryotic expression hosts and culturing the cells so that they express the desired protein. Using an inducible expression cassette the onset of the protein expression can be controlled by several inducer (f.e. chemical, temperature, cold).

Technology
We offer two compact plasmids for facile light regulated expression of target proteins in prokaryotic hosts. Dependent from the application, one plasmid can be used for light activated and one for light inactivated gene expression. Both plasmids are working without exogenous addition of chromophores or expensive chemical inducers and allow a specific, spatially- and temporally precise control of protein expression. A competitive advantage is the use of light as inducer especially for the production of recombinant proteins. Another advantage is the very precise control of protein expression which is very relevant for several research applications. By using standard chemical inducers a spatially and temporally precise control of protein expression is not possible.

IP Rights
None

Origin
Humboldt University, Berlin

Application Area:

Production of proteins in prokaryotes Analysis of protein functions in prokaryotes Pulsed induction of protein expression for several research applications

Development Stage: Product

Schlagworte: Automated induction, Escherichia coli, Light induction, Prokaryote, Protein expression, Pulsed induction, Recombinant protein,

Weitere Kategorien: Life Science, Pharma & Biotech

Licensing Manager: Dr. Bettina Büttner

T +49 30 2125 4835

F +49 30 2125 4822

bettina.buettner@ipal.de

Suitable Industry: Biotechnology and pharmaceutical industry, Research & Development

Benefits:

One plasmid is designed for light inactivated and one for light activated gene expression
Both plasmids are compact and ready-to-use
No exogenous addition of chromophores or chemical inducers is required
System facilitates pulsed and/or automated induction of protein expression
Allows specific, spatially- and temporally-precise control of protein expression
Reduced production costs, because expensive chemical inducers are not required

Stereoselective Synthesis of cis-4-methylsphingosine and derivatives thereof

24.06.2011 | Ref.Nr. 10127

Download as PDF PDF Download Share

Life Science › Pharma&Biotech

Background
Sphingosine-1-phosphate is a bioactive lipid signaling molecule and an agonistic ligand of five specific G protein coupled receptors named S1P1-5.These receptors play a crucial role in the cardiovascular and immune system and in angiogenesis. The known compound FTY720 (Fingolimod) is a sphingosine analogue with immunosuppressive effects and was recently approved for treatment of multiple sclerosis in the United States and Russia.The synthetic sphingosine analogue Cis-4-methylsphingosine was firstly synthesized by R. R. Schmidt and coworkers in 1993 in nine steps.Similar to FTY720 this compound is phosphorylated in biological systems and inhibits the activity of different S1P-receptors, however the spectrum of receptors influenced by Cis-4-methylsphingosine is slightly different to that influenced by FTY720. Cis-4-methylsphingosine induces apoptosis of neuroblastoma cells.

Technology
We offer a rapid and simple method for the stereoselective synthesis of cis-4-methylsphingosine and derivatives thereof in only two steps. The novel synthesis is characterized by using easily accessible starting material, and an overall yield of nearly 30% which is almost 100-fold compared to the synthesis known in the art. Since Cis-4-methylsphingosine also influences S1P-receptors like FTY70, however with a slight different spectrum, this compound might have similar effects or might support or supplement the activity of FTY720. Thereby Cis-4-methysphingosine has a great potential for pharmaceutical application.

IP Rights

EP patent application was filed in May 2011

Patent Owner

Humboldt-Universität zu Berlin

Application Area:

Preparation of cis-4-methylsphingosine

Development Stage: Proof of concept

Schlagworte: cis-4-methylsphingosine, FTY720, stereoselective synthesis,

Weitere Kategorien: Life Science, Pharma & Biotech

Licensing Manager: Dr. Bettina Büttner

T +49 30 2125 4835

F +49 30 2125 4822

bettina.buettner@ipal.de

Suitable Industry: Chemical, biotechnology and pharmaceutical industry

Benefits:

Reliable, easy and rapid method for the preparation of cis-4-methylsphingosine
Only two steps form starting material to cis-4-methylsphingosine
Cost- and time-effective synthesi100-fold higher yield compared to state of the art synthesis

New Pill Package - Applicator for Ointments

12.05.2011 | Ref.Nr. 10049

Download as PDF PDF Download Share

Life Science › Pharma&Biotech

The invention offers two new packaging methods for pills and ointments. Advantage of the packagings is the one-hand operation and the sterile application of the drug.

Pills are fixed on a carrier item that is airtight sealed in a blister-like packaging. It enables the patient to take the pill sterile with one hand from the carrier item. Particularly, the pill goes straight to the mouth of the patient and any contact with the possibly unwashed hands or the non-sterile environment is avoided.

The invented pill dispenser can have marks for the weekdays and daytimes. Additionally it has a fixed patient information leatflet, so that a mixing up with other drugs becomes excluded.

For the sterile application of an ointment a small map packaging was invented. Therefore, the ointment is airtight sealed on a cushion at the end of a rodlike carrier item. The rodlike carrier items are alternating fixed on the map packaging and one map contains as many dosages as needed for one day.

The patient is able to apply target-oriented a defined dosage of one use sterile at every time and everywhere. Therefore, the packaging is special on the way extremely convenient.

IP Rights
German Patent Application, filed on August 6, 2010

Origin
Hochschule für Technik und Wirtschaft Berlin, Germany

Application Area:

Drug packaging

Development Stage: Prototyp

Type of Collaboration: License

Schlagworte: blister, dosage, one-hand, package, pill, sterile,

Weitere Kategorien: Life Science, Medical Devices, Pharma & Biotech

Licensing Manager: Rafaela Kunz

T +49 30 2125 4825

F +49 30 2125 4822

rafaela.kunz@ipal.de

Market Potential: Worldwide

Benefits:

Sterile application of drugs
One-hand operation
Simply application being on the way

Drug screening assay for the detection of Aß42 peptides in the cell nucleus

09.03.2011 | Ref.Nr. 09033

Download as PDF PDF Download Share

Life Science › Pharma&Biotech › Drug delivery

It is known from the state of the art that Ab peptides with 42 amino acids appear to be the key pathogenic species in Alzheimer’s disease, as they are believed to initiate neuronal degeneration. The invention relates to the finding that Ab42 enters neuroblastoma cells and accumulates in the cell nucleus.

We offer a drug-screening assay for the detection of Ab42 accumulation in the cell nucleus of neuroblastoma cells. The new technology is based on the analysis of the cellular and subcellular localization of Ab42 and allows a high throughput identification of compounds that prevent the accumulation of Ab42 in the cell nucleus.
Due to the underlying mechanism that compounds could be:

Inhibitors of the transport of Ab42 into the cells and/or into the cell nucleus
Inhibitors of the dimerization of APP’s
Activator of Ab42 specific degradation
Inhibitor and/or modulator of generegulated function

The identified compounds can preferably be used for the prophylaxis and treatment of neurodegenerative disease, such as Alzheimer’s disease.

IP Rights
A PCT patent application was filed on November 20th, 2010 with priority on November 20th, 2009.

Origin
The assay was developed at the Charité – Universitätsmedizin Berlin and FU Berlin (Germany).

Application Area:

Pharma

Development Stage: In vitro

Type of Collaboration: License

Schlagworte: Alzheimer, Aß42, Cells, Drug, Neurodegenerative disease, Peptides, Screening Method,

Weitere Kategorien: Life Science, Pharma & Biotech, Drug delivery

Licensing Manager: Rafaela Kunz

T +49 30 2125 4825

F +49 30 2125 4822

rafaela.kunz@ipal.de

Market Potential: Worldwide

Benefits:

Fast detection of new drug candidates
High throughput capable assay
Cost-saving technology
Insights for the mode of action and better chances for drug approval

Peptides for Diagnosis and Therapy of Celery Allergy and of Hazelnut Allergy

10.11.2010 | Ref.Nr. 10048

Download as PDF PDF Download Share

Life Science › Diagnostics

Novel linear IgE-binding peptide epitopes of the major celery allergen api g1 have been identified which are suitable for the diagnosis and therapy of celery allergy. The peptide epitopes can also serve as a basis for the detection of api g1 allergens in food and other products. Based on the novel peptides, a high specific assay was developed which allows to distinguish between celery allergic patients and healthy individuals.

Celery is a frequent cause of food allergy in pollen-sensitized patients and may induce severe allergic reactions. Allergic reactions against celery are of major clinical relevance due to celery's wide presence in convenience foods and spice. Approximately 3% - 4% of the European or American population and 5% of young children are affected by immunoglobulin E (IgE) mediated food allergy; 30% of them are sensitized to celery. The symptoms ranging from mild oral pruritus to a possible life-threatening anaphylactic shock.

IP Rights
An EP application was filed in July 2010.

Origin
The invention was made at the Charité – Universitätsmedizin Berlin.

Application Area:

Pharma, Diagnostic, Food analytic

Development Stage: Pilot study, in vitro

Type of Collaboration: Licence

Schlagworte: Allergen, Allergy, Celery, Diagnosis, Food, Hazelnut, Peptide, Therapy,

Weitere Kategorien: Diagnostics, Immunology & Infection, Nutrition, Pharma & Biotech

Licensing Manager: Dr. Bettina Büttner

T +49 30 2125 4835

F +49 30 2125 4822

bettina.buettner@ipal.de

Market Potential: Worldwide

Benefits:

Allows a specific and fast identification of the api 1g allergen in celery allergic patients
More reliable results compared to PCR- or state of the art- IgE-detection approaches are supposed
Peptide is suitable for chip applications and automatable methods
The novel peptides can be used for the desensitization of patients (Immunotherapy)